Wayne H Winegarden
Featured
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
Drug Pricing
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
California
NEW STUDY: Californians Could Save More Than $2,000 Annually if Lawmakers Enacted Free-Market Energy Policies
If lawmakers acted to alleviate the unnecessary costs from state energy mandates, Californians living through these unprecedented times could save more than $2,000 annually – while still lowering emissions – finds a new study released today by the nonpartisan Pacific Research Institute and Power the Future. Click here to download ...
Business & Economics
Wayne Winegarden quoted in Washington Examiner on trade wars
Fears that the President’s Trump’s trade war with China will lead to a recession may have faded from the headlines, but economists say it cannot be discounted. “We’re not expecting a recession anytime soon, but, that said, there are a number of headwinds, ranging from slower growth, trade tensions, a gradual erosion ...
Commentary
Defining a Medicines’ Value versus its Price
When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value ...
Health Care
Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief
The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical ...
Business & Economics
New Study Finds ESG Funds Underperform Broader Investment Funds Over Long-Term
ESG funds that champion environmental and social causes have historically underperformed funds investing in the broader market over the long-term, so finds a new study released today by California-based, free-market think tank, the Pacific Research Institute. “In recent years, ESG funds have been presented to investors as socially responsible as ...
Blog
NEW STUDY: Costly Regulations Hurt Entrepreneurship, Reform Needed to ‘Break Down Barriers’ for Jobs, Innovation
Costly regulations serve as a barrier to entrepreneurship, small business growth, innovation, and job opportunities to lift people into the middle class, concludes the first paper in a new series from the California-based, free-market think tank, the Pacific Research Institute. Click here to download the first paper in the Breaking ...
Health Care
New PRI Study: Congress Has Some Unfinished Business – Acting to Repeal the Medical Device Tax
The controversial medical device tax hurts doctors, patients and manufacturers and should be repealed by Congress – according a new study released today by the California-based, free-market think tank, the Pacific Research Institute. Click here to download a copy of the study. “As the congressional session winds down, Congress has ...
Business & Economics
New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
NEW STUDY: Californians Could Save More Than $2,000 Annually if Lawmakers Enacted Free-Market Energy Policies
If lawmakers acted to alleviate the unnecessary costs from state energy mandates, Californians living through these unprecedented times could save more than $2,000 annually – while still lowering emissions – finds a new study released today by the nonpartisan Pacific Research Institute and Power the Future. Click here to download ...
Wayne Winegarden quoted in Washington Examiner on trade wars
Fears that the President’s Trump’s trade war with China will lead to a recession may have faded from the headlines, but economists say it cannot be discounted. “We’re not expecting a recession anytime soon, but, that said, there are a number of headwinds, ranging from slower growth, trade tensions, a gradual erosion ...
Defining a Medicines’ Value versus its Price
When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value ...
Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief
The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical ...
New Study Finds ESG Funds Underperform Broader Investment Funds Over Long-Term
ESG funds that champion environmental and social causes have historically underperformed funds investing in the broader market over the long-term, so finds a new study released today by California-based, free-market think tank, the Pacific Research Institute. “In recent years, ESG funds have been presented to investors as socially responsible as ...
NEW STUDY: Costly Regulations Hurt Entrepreneurship, Reform Needed to ‘Break Down Barriers’ for Jobs, Innovation
Costly regulations serve as a barrier to entrepreneurship, small business growth, innovation, and job opportunities to lift people into the middle class, concludes the first paper in a new series from the California-based, free-market think tank, the Pacific Research Institute. Click here to download the first paper in the Breaking ...
New PRI Study: Congress Has Some Unfinished Business – Acting to Repeal the Medical Device Tax
The controversial medical device tax hurts doctors, patients and manufacturers and should be repealed by Congress – according a new study released today by the California-based, free-market think tank, the Pacific Research Institute. Click here to download a copy of the study. “As the congressional session winds down, Congress has ...
New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
